CL2017002474A1 - Combinaciones antihelmínticas y los métodos de usos de las mismas - Google Patents

Combinaciones antihelmínticas y los métodos de usos de las mismas

Info

Publication number
CL2017002474A1
CL2017002474A1 CL2017002474A CL2017002474A CL2017002474A1 CL 2017002474 A1 CL2017002474 A1 CL 2017002474A1 CL 2017002474 A CL2017002474 A CL 2017002474A CL 2017002474 A CL2017002474 A CL 2017002474A CL 2017002474 A1 CL2017002474 A1 CL 2017002474A1
Authority
CL
Chile
Prior art keywords
methods
prophylaxis
treatment
macrocyclic lactone
anthelmintic
Prior art date
Application number
CL2017002474A
Other languages
English (en)
Spanish (es)
Inventor
Brenda Bondesen
Lance Hammerland (Fallecido)
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of CL2017002474A1 publication Critical patent/CL2017002474A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2017002474A 2015-04-02 2017-10-02 Combinaciones antihelmínticas y los métodos de usos de las mismas CL2017002474A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562142304P 2015-04-02 2015-04-02

Publications (1)

Publication Number Publication Date
CL2017002474A1 true CL2017002474A1 (es) 2018-03-23

Family

ID=57006415

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002474A CL2017002474A1 (es) 2015-04-02 2017-10-02 Combinaciones antihelmínticas y los métodos de usos de las mismas

Country Status (18)

Country Link
US (1) US10993988B2 (https=)
EP (1) EP3277303B1 (https=)
JP (1) JP6899330B2 (https=)
KR (1) KR20170132330A (https=)
CN (1) CN107567334A (https=)
AU (1) AU2016244022A1 (https=)
BR (1) BR112017020975A2 (https=)
CA (1) CA2981489A1 (https=)
CL (1) CL2017002474A1 (https=)
CO (1) CO2017011284A2 (https=)
ES (1) ES2851345T3 (https=)
IL (1) IL254783B (https=)
MX (1) MX381319B (https=)
MY (1) MY187835A (https=)
PH (1) PH12017501806A1 (https=)
RU (1) RU2717545C2 (https=)
SG (1) SG11201708008TA (https=)
WO (1) WO2016161369A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541789A1 (en) * 2016-11-16 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic depsipeptide compounds
PT3579696T (pt) * 2017-02-08 2023-07-19 Boehringer Ingelheim Animal Health Usa Inc Modelo in vivo para infeção por vermes parasitários e métodos para avaliação de compostos antiparasíticos, que incluem compostos ativos contra a dirofilariose canina
BR112020010291A2 (pt) 2017-11-23 2020-11-17 Ceva Sante Animale composição contendo moxidectina para tratamento de infestações de parasitas
MX2020005573A (es) * 2017-11-29 2020-09-10 Zoetis Services Llc Depsipeptidos endoparasitarios.
AR116524A1 (es) * 2018-10-04 2021-05-19 Elanco Tiergesundheit Ag Potenciación de tratamiento de helmintos
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations
GB202100635D0 (en) * 2021-01-18 2021-03-03 Liverpool School Tropical Medicine Compounds and methods for treating or preventing dirofilaria infection in a mammal
US11999742B2 (en) 2021-11-01 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134973A (en) 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
GB9300883D0 (en) 1993-01-18 1993-03-10 Pfizer Ltd Antiparasitic agents
DE19520275A1 (de) * 1995-06-02 1996-12-05 Bayer Ag Endoparasitizide Mittel
US20030129680A1 (en) 2001-10-31 2003-07-10 O'connor Thomas Patrick Multi-analyte assay device
US20070042354A1 (en) 2005-08-19 2007-02-22 Engelhard Eric K Detecting pathogens in companion animals
ES2367332T3 (es) * 2007-02-21 2011-11-02 Pfizer Limited Agentes antiparasitarios de benzofurano.
JP4734656B2 (ja) 2007-03-30 2011-07-27 国立大学法人群馬大学 Pf1022類の製造法
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US8809268B2 (en) 2008-10-29 2014-08-19 The Regents Of The University Of California Combination therapy to combat helminth resistance
BE1019407A5 (nl) 2009-11-06 2012-07-03 Momentum Animal Cure Bvba Middel voor het uitdrijven van parasieten bij mensen, dieren en vogels.
CN102741252A (zh) 2010-02-05 2012-10-17 英特维特国际股份有限公司 用作驱虫剂的螺吲哚啉化合物
US9758840B2 (en) 2010-03-14 2017-09-12 Ibis Biosciences, Inc. Parasite detection via endosymbiont detection
RU2452180C2 (ru) 2010-08-31 2012-06-10 Общество с ограниченной ответственностью "Научно-внедренческое предприятие "Астрафарм" Комплексная антипаразитарная композиция
AU2010249226C1 (en) 2010-12-08 2017-04-13 Zoetis Services Llc Anthelmintic formulation
AU2010101389C4 (en) 2010-12-08 2017-03-02 Jurox Pty Ltd Anthelmintic formulation
US9096599B2 (en) 2011-08-04 2015-08-04 Intervet Inc. Spiroindoline compounds

Also Published As

Publication number Publication date
MY187835A (en) 2021-10-26
IL254783A0 (en) 2017-12-31
CA2981489A1 (en) 2016-10-06
EP3277303A1 (en) 2018-02-07
PH12017501806A1 (en) 2018-04-11
CN107567334A (zh) 2018-01-09
BR112017020975A2 (pt) 2018-07-10
RU2717545C2 (ru) 2020-03-24
CO2017011284A2 (es) 2018-01-31
MX2017012510A (es) 2018-01-30
MX381319B (es) 2025-03-12
SG11201708008TA (en) 2017-10-30
JP2018510195A (ja) 2018-04-12
ES2851345T3 (es) 2021-09-06
IL254783B (en) 2020-11-30
US20170020955A1 (en) 2017-01-26
JP6899330B2 (ja) 2021-07-07
RU2017138118A (ru) 2019-05-06
US10993988B2 (en) 2021-05-04
RU2017138118A3 (https=) 2019-07-24
WO2016161369A1 (en) 2016-10-06
AU2016244022A1 (en) 2017-10-26
KR20170132330A (ko) 2017-12-01
EP3277303B1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
CL2017002474A1 (es) Combinaciones antihelmínticas y los métodos de usos de las mismas
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
MX385876B (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
CL2017003404A1 (es) Compuestos antibacterianos
UY37563A (es) Aislados de bacillus y usos de los mismos
CO7350655A2 (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
CL2012002782A1 (es) Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros.
MX2017004600A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
CU20170153A7 (es) Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
IL253619A0 (en) Encapsulation of high potency active agents
MX2019011271A (es) Compuestos y metodos para el tratamiento de enfermedades parasitarias.
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
CL2018000253A1 (es) Respuesta inmunitaria potenciada de las especies porcinas
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..
PE20151726A1 (es) Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas